• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Praxis Precision Medicines Inc.

    2/28/25 8:52:15 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRAX alert in real time by email
    S-8 1 tm257736d2_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on February 28, 2025

     

    Registration No. 333- 

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    PRAXIS PRECISION MEDICINES, INC.

    (Exact name of registrant as specified in its charter)

     

     

    Delaware   47-5195942
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification No.)

     

    99 High Street, 30th Floor

    Boston, MA 02110

    (Address of Principal Executive Offices) (Zip Code)

     

    Praxis Precision Medicines, Inc. 2024 Inducement Plan

    (Full title of the plan)

     

    Marcio Souza

    Chief Executive Officer

    Praxis Precision Medicines, Inc.

    99 High Street, 30th Floor

    Boston, MA 02110

    (Name and address of agent for service)

     

    (617) 300-8460

    (Telephone number, including area code, of agent for service)

     

    Copies to:

    Peter N. Handrinos

    Jennifer A. Yoon

    Latham & Watkins LLP

    200 Clarendon Street

    Boston, MA 02116

    (617) 948-6060

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer x Accelerated filer ¨
           
    Non-accelerated filer ¨ Smaller reporting company ¨
           
        Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ¨

     

     

     

     

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The information called for in Part I of Form S-8 is not being filed with or included in this Registration Statement (by incorporation by reference or otherwise) in accordance with the rules and regulations of the Securities and Exchange Commission (the “Commission”).

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents filed with the Commission are hereby incorporated by reference in this Registration Statement:

     

     (a)the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Commission on February 28, 2025 (File No. 001-39620); and
     (b)the Registrant’s Registration Statement on Form 8-A filed with the Commission on October 14, 2020 (File No. 001-39620) pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), relating to the Registrant’s common stock, as updated by “Description of Securities of Praxis Precision Medicines, Inc.” filed as Exhibit 4.3 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed with the Commission on February 28, 2022 (File No. 001-39620), and any amendment or report filed for the purpose of updating such description.

     

    All reports and other documents filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, after the date hereof (except for any portions of the Registrant’s Current Reports on Form 8-K furnished pursuant to Item 2.02 and/or Item 7.01 thereof and any corresponding exhibits thereto not filed with the Commission) and prior to the filing of a post-effective amendment to this Registration Statement, which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part hereof from the date of filing of such documents or reports.

     

    Any statement contained in this Registration Statement, in an amendment hereto or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed amendment to this Registration Statement or in any document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement, except as to specific section of such statements as set forth therein.

     

    Under no circumstances shall any information furnished under Item 2.02 and/or Item 7.01 of Current Reports on Form 8-K and any corresponding exhibits thereto be deemed incorporated herein by reference unless such Current Report on Form 8-K expressly provides to the contrary.

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

     

     

     

     

    Item 6. Indemnification of Directors and Officers.

     

    Subsection (a) of Section 145 of the General Corporation Law of the State of Delaware (the “DGCL”), empowers a corporation to indemnify any person who was or is a party or who is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the person’s conduct was unlawful.

     

    Subsection (b) of Section 145 of the DGCL empowers a corporation to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that the person acted in any of the capacities set forth above, against expenses (including attorneys’ fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.

     

    Section 145 of the DGCL further provides that to the extent a director or officer of a corporation has been successful on the merits or otherwise in the defense of any action, suit or proceeding referred to in subsections (a) and (b) of Section 145 of the DGCL, or in defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection therewith; that indemnification provided for by Section 145 of the DGCL shall not be deemed exclusive of any other rights to which the indemnified party may be entitled; and the indemnification provided for by Section 145 of the DGCL shall, unless otherwise provided when authorized or ratified, continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of such person’s heirs, executors and administrators. Section 145 of the DGCL also empowers the corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of such person’s status as such, whether or not the corporation would have the power to indemnify such person against such liabilities under Section 145 of the DGCL.

     

    Section 102(b)(7) of the DGCL provides that a corporation’s certificate of incorporation may contain a provision eliminating or limiting the personal liability of a director or officer to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or officer, provided that such provision shall not eliminate or limit the liability of (i) a director or officer for any breach of the director’s or officer’s duty of loyalty to the corporation or its stockholders, (ii) a director or officer for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) a director under Section 174 of the DGCL, (iv) a director or officer for any transaction from which the director or officer derived an improper personal benefit, or (v) an officer in any action by or in the right of the corporation.

     

     

     

     

    The Registrant has adopted provisions in its Amended and Restated Certificate of Incorporation that limit or eliminate the personal liability of its directors to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended. Consequently, a director or officer will not be personally liable to the Registrant or its stockholders for monetary damages or breach of fiduciary duty as a director or officer, except for liability:

     

     ·any breach of the director’s duty of loyalty to the Registrant or its stockholders;
       
     ·any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
       
     ·under Section 174 of the DGCL; or
       
     ·any transaction from which the director derived an improper personal benefit.

     

    These limitations of liability do not alter director liability under the federal securities laws and do not affect the availability of equitable remedies such as an injunction or rescission.

     

    In addition, the Registrant’s Amended and Restated Bylaws provide that:

     

     ·the Registrant will indemnify its directors, officers and, in the discretion of its board of directors, certain employees to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended; and
       
     ·the Registrant will advance reasonable expenses, including attorneys’ fees, to its directors and, in the discretion of its board of directors, to its officers and certain employees, in connection with legal proceedings relating to their service for or on behalf of the Registrant, subject to limited exceptions.

     

    The Registrant has entered into indemnification agreements with each of its directors and executive officers. These agreements provide that the Registrant will indemnify each of its directors, executive officers and, at times, their affiliates to the fullest extent permitted by Delaware law. The Registrant will advance expenses, including attorneys’ fees (but excluding judgments, fines and settlement amounts), to each indemnified director, executive officer or affiliate in connection with any proceeding in which indemnification is available and will indemnify its directors and officers for any action or proceeding arising out of that person’s services as a director or officer brought on behalf of the Registrant or in furtherance of its rights. Additionally, certain of the Registrant’s directors may have certain rights to indemnification, advancement of expenses or insurance provided by their affiliates or other third parties, which indemnification relates to and might apply to the same proceedings arising out of such director’s services as a director referenced herein. Nonetheless, the Registrant has agreed in the indemnification agreements that its obligations to those same directors are primary and any obligation of such affiliates or other third parties to advance expenses or to provide indemnification for the expenses or liabilities incurred by those directors are secondary.

     

    The Registrant also maintains general liability insurance which covers certain liabilities of its directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers, including liabilities under the Securities Act of 1933, as amended.

     

    Item 7. Exemption from Registration Claimed.

     

    Not applicable.

     

     

     

     

    Item 8.Exhibits

     

    Exhibit
    Number
      Description of Exhibit
         
    4.1   Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-39620) filed with the Securities and Exchange Commission on October 20, 2020)
         
    4.2   Certificate of Amendment to the Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-39620) filed with the Securities and Exchange Commission on December 1, 2023)
         
    4.3   Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-39620) filed with the Securities and Exchange Commission on January 7, 2022)
         
    5.1*   Opinion of Latham & Watkins LLP
         
    23.1*   Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm
         
    23.2*   Consent of Latham & Watkins LLP (included in Exhibit 5.1)
         
    24.1   Power of Attorney (included on signature page)
         
    99.1   Praxis Precision Medicines, Inc. 2024 Inducement Plan and Forms of Award Agreements thereunder (Incorporated by reference to Exhibit 99.1 to the Registrant’s Registration Statement on Form S-8 (File No. 333-276786) filed with the Securities and Exchange Commission on January 31, 2024).
         
    107.1*   Filing Fee Table

     

    * Filed herewith

     

    Item 9.Undertakings

     

    (a) The undersigned Registrant hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee Tables” table in the effective Registration Statement; and

     

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement; provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply if the Registration Statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

     

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

     

     

     

    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (h) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Commonwealth of Massachusetts, on this 28th day of February, 2025.

     

      PRAXIS PRECISION MEDICINES, INC.
       
      By: /s/ Marcio Souza
      Name: Marcio Souza
      Title:   Chief Executive Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Marcio Souza and Timothy Kelly, or either of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to file and sign any and all amendments, including post-effective amendments, to this registration statement, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes may lawfully do or cause to be done by virtue hereof. This power of attorney shall be governed by and construed with the laws of the State of Delaware and applicable federal securities laws.

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    SIGNATURE   TITLE   DATE
             
    /s/ Marcio Souza   Chief Executive Officer and Director   February 28, 2025
    Marcio Souza   (Principal Executive Officer)    
             
    /s/ Timothy Kelly   Chief Financial Officer   February 28, 2025
    Timothy Kelly   (Principal Financial Officer)    
             
    /s/ Lauren Mastrocola   Principal Accounting Officer   February 28, 2025
    Lauren Mastrocola        
             
    /s/ Dean Mitchell   Chairman of the Board   February 28, 2025
    Dean Mitchell        
             
    /s/ Jeffrey Chodakewitz   Director   February 28, 2025
    Jeffrey Chodakewitz, M.D.        
             
    /s/ Merit Cudkowicz   Director   February 28, 2025
    Merit Cudkowicz, M.D.        
             
    /s/ Jill DeSimone   Director   February 28, 2025
    Jill DeSimone        
             
    /s/ Gregory Norden   Director   February 28, 2025
    Gregory Norden        
             
    /s/ William Young   Director   February 28, 2025
    William Young        

     

     

     

    Get the next $PRAX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PRAX

    DatePrice TargetRatingAnalyst
    5/7/2025$80.00Buy
    Chardan Capital Markets
    3/3/2025$120.00 → $105.00Buy
    H.C. Wainwright
    2/11/2025$111.00Buy
    Deutsche Bank
    8/5/2024$134.00Outperform
    Oppenheimer
    6/24/2024$145.00Buy
    Needham
    6/18/2024$155.00Buy
    Guggenheim
    5/1/2024$117.00Outperform
    Robert W. Baird
    9/19/2023$10.00Buy
    Truist
    More analyst ratings

    $PRAX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event

      BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, hosted a virtual investor event on its clinical programs in developmental and epileptic encephalopathies (DEEs) on Friday, May 2, 2025. "We were excited to highlight the significant opportunity in DEEs and progress Praxis is making in this field," said Marcio Souza, president and chief executive officer of Praxis. "Relutrigine continues to show tremendous promise to broadly address the DEE market

      5/5/25 8:00:00 AM ET
      $IONS
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      BOSTON, May 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on May 1, 2025, the Compensation Committee of Praxis' Board of Directors granted restricted stock unit awards covering an aggregate of 3,688 shares of its common stock to five new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock units were granted as inducements material to the employees' en

      5/2/25 5:00:00 PM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results

      On track for six major study readouts across four programs over the next 12 months Ready to initiate pivotal studies in two developmental and epileptic encephalopathy (DEE) programs in mid-year 2025: EMERALD for broad DEEs with relutrigine and EMBRAVE3 for SCN2A GoF with elsunersen Vormatrigine continues to generate a best-in-class safety profile with new data demonstrating no food effect and higher dosing tolerability Praxis to host a virtual investor event on Friday, May 2, 2025 to discuss its DEE portfolio [registration link] Cash and investments of $472 million as of March 31, 2025, maintains runway into 2028 BOSTON, May 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc

      5/2/25 8:30:00 AM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRAX
    Financials

    Live finance-specific insights

    See more
    • GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025

      Grew fourth quarter 2024 revenues1 to $95.3 million Expanded fourth quarter 2024 adjusted gross margins1,2 to 70% Generated fourth quarter 2024 adjusted net income2 of $16.8 million FY 2025 revenue guidance of $350M to $360M, exome/genome volume and revenue growth of at least 30% GeneDx to host conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the fourth quarter and full year of 2024. "The fourth quarter capped an outstanding year for GeneDx, as we work to end the diagnostic odyssey with earlier intervention using our industry-leading exome and gen

      2/18/25 6:00:00 AM ET
      $BIIB
      $PRAX
      $STOK
      $WGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Retail: Computer Software & Peripheral Equipment
    • Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results

      Interim analysis for Study 1 of Essential3 Phase 3 program for ulixacaltamide in essential tremor (ET) confirmed for Q1 2025; NDA filing anticipated in 2025 Registrational Cohort 2 of EMBOLD study recruiting following unprecedented seizure freedom seen in positive topline EMBOLD results for Cohort 1 in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) Vormatrigine (PRAX-628) on track for topline from POWER1 study in focal epilepsy and RADIANT study in focal and generalized epilepsy in 2025 Maintains runway into 2027 BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic i

      11/6/24 7:30:00 AM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024

      BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced it will report its financial results from the third quarter ended September 30, 2024, before the financial markets open on Wednesday, November 6, 2024. The Company will host a live webcast the same morning at 8am ET, which can be accessed by visiting this registration link. This live webcast will also be available through the Events & Presentations page of the Investors + Media se

      11/1/24 8:00:00 AM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • General Counsel and Secretary Nemiroff Alex covered exercise/tax liability with 51 shares, decreasing direct ownership by 0.24% to 20,832 units (SEC Form 4)

      4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)

      2/14/25 4:29:47 PM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Principal Accounting Officer Mastrocola Lauren covered exercise/tax liability with 40 shares, decreasing direct ownership by 0.38% to 10,442 units (SEC Form 4)

      4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)

      2/14/25 4:29:37 PM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Souza Marcio covered exercise/tax liability with 401 shares, decreasing direct ownership by 0.74% to 53,559 units (SEC Form 4)

      4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)

      2/14/25 4:29:25 PM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRAX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Desimone Jill bought $25,375 worth of shares (14,500 units at $1.75) (SEC Form 4)

      4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)

      10/10/23 7:41:39 AM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $PRAX
    Leadership Updates

    Live Leadership Updates

    See more

    $PRAX
    SEC Filings

    See more
    • Chardan Capital Markets initiated coverage on Praxis Precision Medicines with a new price target

      Chardan Capital Markets initiated coverage of Praxis Precision Medicines with a rating of Buy and set a new price target of $80.00

      5/7/25 8:38:09 AM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright reiterated coverage on Praxis Precision Medicines with a new price target

      H.C. Wainwright reiterated coverage of Praxis Precision Medicines with a rating of Buy and set a new price target of $105.00 from $120.00 previously

      3/3/25 7:53:12 AM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Deutsche Bank initiated coverage on Praxis Precision Medicines with a new price target

      Deutsche Bank initiated coverage of Praxis Precision Medicines with a rating of Buy and set a new price target of $111.00

      2/11/25 7:11:28 AM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2022 Financial Results

      PRAX-944 Phase 2b Essential1 Study topline results expected in 4Q22; primary endpoint updated to efficacy PRAX-562 Phase 1 study completed, confirming biomarker change and potential for wide therapeutic window Cash and investments of $165.4 million as of June 30, 2022 supports runway into 1Q24 BOSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided a corporate update and reported financial results for the second quarter of 2022

      8/8/22 4:01:00 PM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Praxis Precision Medicines Adds Global Business Expertise to Board of Directors with Appointment of Jill DeSimone

      BOSTON, May 23, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the appointment of Jill DeSimone to its board of directors. "We are very excited to have Jill join the Praxis board of directors. She is an ideal fit for the Praxis board with her impressive background as a global business leader for multi-billion-dollar products, unique insights into product strategy and portfolio prioritization, and breadth of experience advocating for excellence

      5/23/22 9:00:00 AM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Praxis Precision Medicines Announces Management Team Appointments

      BOSTON, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today announced the appointment of Megan Sniecinski as chief business officer and provided key updates on members of the executive leadership team. Praxis has promoted Alyssa Wyant to chief regulatory and quality officer and Karl Hansen, Ph.D., to chief technical operations officer. In addition, chief scientific officer and co-founder, Steven Petrou, Ph.D., has decided to fully dedicate his time to Praxis upon stepping

      12/2/21 7:00:00 AM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Praxis Precision Medicines Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Praxis Precision Medicines, Inc. (0001689548) (Filer)

      5/2/25 5:12:19 PM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Praxis Precision Medicines Inc.

      10-Q - Praxis Precision Medicines, Inc. (0001689548) (Filer)

      5/2/25 8:38:06 AM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Praxis Precision Medicines Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Praxis Precision Medicines, Inc. (0001689548) (Filer)

      5/2/25 8:35:39 AM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Praxis Precision Medicines Inc.

      SC 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)

      11/14/24 7:53:30 PM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Praxis Precision Medicines Inc.

      SC 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)

      11/14/24 5:50:15 PM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Praxis Precision Medicines Inc.

      SC 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)

      11/14/24 5:46:12 PM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care